Literature DB >> 7858501

Follicular dendritic cells in non-Hodgkin's lymphomas.

S Petrasch1, G Brittinger, H H Wacker, J Schmitz, M Kosco-Vilbois.   

Abstract

Follicular dendritic cells (FDC) are restricted to the B-cell regions of secondary lymphoid tissue and to non-Hodgkin's lymphomas derived from the follicular center or the mantle zone. With their cytoplasmic ramifications they form a dense network which contains the B-lymphocytes. In situ, FDC are only detectable at the ultrastructural level or when stained with anti FDC-reagents. On the surface of their dendritic extensions they express transferrin receptors (CD71), the B-cell epitope CD20, class II antigens, the myelomonocytic molecule CD14, the glycoprotein gp50 (CD40), and several receptors for components of the complement system (CD11b, CD21, CD35). Subsequent to an antigen challenge, FDC trap and retain immune-complexes for a long period of time. In vitro FDC and neoplastic lymphocytes spontaneously form small cellular aggregates. This adhesion is mediated by the LFA-1-alpha/beta = ICAM-1, the VLA-4 = VCAM-1, and the ICAM-1 = C3bi- receptor ligand pathways on B-cells and on FDC, respectively. The loss of LFA-1- alpha/beta and ICAM-1 molecules may enable neoplastic lymphocytes to detach from FDC. The monoclonal B-cells now invade new compartments. In vitro, FDC have the capacity to activate resting B-cells and to save them from dying by apoptosis. Signals involved in this activation include cell-surface immunoglobulin and CD40. Immunocytochemistry and autoradiography with single cell suspensions of neoplastic B cells suggest that FDC also provide signals leading to the continued stimulation of lymphoma lymphocytes. During the early stage of HIV infection lymph nodes show an immense follicular hyperplasia, with a massive increase of the dendritic network of FDC. In the later stage of the disease, the continuous involution of the germinal centers is associated with a progressive destruction of FDC.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7858501     DOI: 10.3109/10428199409051675

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  6 in total

1.  Dendritic cells interacting mainly with B cells in the lymphoepithelial symbiosis of the human palatine tonsil.

Authors:  Kiyoshi Takahashi; Yuriko Nishikawa; Hiaki Sato; Takashi Oka; Tadashi Yoshino; Katsuya Miyatani
Journal:  Virchows Arch       Date:  2006-03-08       Impact factor: 4.064

2.  Growth pattern and distribution of follicular dendritic cells in mantle cell lymphoma: a clinicopathological study of 96 patients.

Authors:  Carsten Schrader; Peter Meusers; Günter Brittinger; Dirk Janssen; Afshin Teymoortash; Jens U Siebmann; Reza Parwaresch; Markus Tiemann
Journal:  Virchows Arch       Date:  2005-08-17       Impact factor: 4.064

3.  In vivo expression of interleukin-8, and regulated on activation, normal, T-cell expressed, and secreted, by human germinal centre B lymphocytes.

Authors:  Jennifer C Sims-Mourtada; Liliana Guzman-Rojas; Roberto Rangel; Dat X Nghiem; Stephen E Ullrich; Christiane Guret; Kelly Cain; Hector Martinez-Valdez
Journal:  Immunology       Date:  2003-11       Impact factor: 7.397

4.  Neutrophils protect lymphoma cells against cytotoxic and targeted therapies through CD11b/ICAM-1 binding.

Authors:  Taghreed Hirz; Eva-Laure Matera; Kamel Chettab; Lars Petter Jordheim; Doriane Mathé; Anne Evesque; Justine Esmenjaud; Gilles Salles; Charles Dumontet
Journal:  Oncotarget       Date:  2017-08-18

5.  3D analyses reveal T cells with activated nuclear features in T-cell/histiocyte-rich large B-cell lymphoma.

Authors:  Aresu Sadeghi Shoreh Deli; Sonja Scharf; Yvonne Steiner; Julia Bein; Martin-Leo Hansmann; Sylvia Hartmann
Journal:  Mod Pathol       Date:  2022-02-16       Impact factor: 8.209

6.  Fibroblasts in Nodular Sclerosing Classical Hodgkin Lymphoma Are Defined by a Specific Phenotype and Protect Tumor Cells from Brentuximab-Vedotin Induced Injury.

Authors:  Katrin Bankov; Claudia Döring; Adam Ustaszewski; Maciej Giefing; Marco Herling; Chiara Cencioni; Francesco Spallotta; Carlo Gaetano; Ralf Küppers; Martin-Leo Hansmann; Sylvia Hartmann
Journal:  Cancers (Basel)       Date:  2019-10-30       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.